Recently, ResMed (RMD) has been experiencing significant financial shifts. Goldman Sachs removed the stock from their APAC Conviction List, resulting in immediate valuation concerns for RMD. Despite this, various financial groups such as Baird Financial Group Inc. and Invesco Ltd. have maintained considerable holdings in ResMed, showcasing its favoured position by institutional investors. Moreover, RMD has reported strong revenue growth and strategic innovations which are reflective in their earnings calls.
Other key developments include ResMed's launch of new mask platforms and investments into U.S operations which indicates a proactive approach to improve their product and services. Despite some insider sales, various entities including Quantbot Technologies LP, Norges Bank, and Russell Investments Group Ltd. have increased their stakes in RMD. However, ResMed's stock performance has not been positively consistent, with multiple days of loss streaks. Regardless, analysts project a possible future rally in the stock price of RMD by 2028.
Resmed RMD News Analytics from Thu, 24 Apr 2025 07:00:00 GMT to Fri, 05 Dec 2025 20:28:28 GMT - Rating 3 - Innovation 2 - Information 6 - Rumor -2
